Have You or a Loved One Been Diagnosed With Macular Degeneration?

Age-related macular degeneration (AMD) is the leading cause of irreversible blindness and vision loss in the developed world, accounting for more than 50% of all vision loss in the United States. If you or a loved one have received this diagnosis, you probably have questions.

Kids-picture-Advanced-AMD v2AMD is a disease that destroys your sharp, central vision. You need central vision to see objects clearly and to do tasks such as reading, driving, and recognizing faces.

AMD affects the macula, the part of the eye that allows you to see fine detail. It does not hurt, but it causes cells in the macula to die. There are two types of Macular Degeneration, dry AMD (Atrophic) and the more serious type, wet AMD (Neovascular).

AMD Types

Dry AMD:
Accounts for 80-90% of all cases of AMD. In dry AMD small white or yellow deposits form on the retina underneath the macula. These deposits are called Most AMD begins as the dry type and in some cases progresses to the wet type. There are three stages of dry AMD:

Continue reading Have You or a Loved One Been Diagnosed With Macular Degeneration?

Is Age-Related Macular Degeneration Affecting You?

Lutein + Zeaxanthin and Omega-3 Fatty Acids for Age-Related Macular Degeneration.
The Age-Related Eye Disease Study 2 (AREDS2) Randomized Clinical Trial 

This Research brief is summarized from a published clinical study. All the information and statistics cited below were taken directly from the original publication authored by the Age-Related Eye Disease Study 2 (AREDS2) Research Group. Doctor’s Advantage Products, LLC has restructured or paraphrased some sections of this brief in an attempt to more succinctly summarize the research.

older-business-womanAge-related macular degeneration (AMD), the leading cause of blindness in the developed world, accounts for more than 50% of all blindness in the United States. Although intraocular drugs that inhibit vascular endothelial growth factor are currently available for treatment of neovascular AMD, no effective therapies are proven for atrophic AMD. 

The Age-Related Eye Disease Study (AREDS) demonstrated that daily oral supplementation with antioxidant vitamins and minerals reduced the risk of developing advanced AMD by 25% at 5 years. Observational studies suggest that higher dietary intake of lutein + zeaxanthin, omega-3 long-chain polyunsaturated fatty acids and eicosapentaenoic acid, or both are associated with a decreased risk of developing advanced AMD.  Continue reading Is Age-Related Macular Degeneration Affecting You?

We’ve Updated Our Formula

Doctor’s Advantage Products, LLC, (“Doctor’s Advantage”) would like to update you regarding product modifications with two of our products, Macular Shield and Macular Shield plus Complete Multivitamin.  As you know, the Age-Related Eye Disease Study 2 (“AREDS 2”) showed that a daily nutritional supplement containing a unique formulation of high-dose ingredients can possibly slow the progression of Age-Related Macular Degeneration (“ARMD”) and may even reduce the risk of developing advanced ARMD.
New-Formula
Our macular degeneration products, Macular Shield and Macular Shield plus Complete Multivitamin both contain AREDS 2 ingredients.  The AREDS 2 study also analyzed the ingredient zinc between dosages of 25 mg and 80 mg.  Currently, our products contain 80 mg of zinc.  The AREDS 2 study revealed that 25 mg of zinc may be as beneficial as 80 mg of zinc.  Other studies suggest that certain side effects may occur with high dose zinc supplementation, which include the following: Continue reading We’ve Updated Our Formula